© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Amodiaquine Hydrochloride entered the malaria treatment scene in the mid-20th century, a period marked by worldwide efforts to control parasitic diseases. The need for alternatives to chloroquine, which faced growing resistance from Plasmodium falciparum, pushed scientists to explore structural analogs. French chemists synthesized amodiaquine after modifying the basic 4-aminoquinoline backbone of chloroquine, aiming for improved activity and tolerability in tropical climates. For several decades, healthcare workers across Africa, Asia, and South America counted on amodiaquine to reduce childhood mortality and disrupt cycles of malarial infection. Its journey also became a lesson in pharmacovigilance, as reports from the late 1980s revealed rare but serious side effects, including agranulocytosis and hepatitis. Researchers and clinicians learned quickly that even old tools require constant scrutiny.
Amodiaquine Hydrochloride forms the backbone for malaria therapy, either as a monotherapy or, more commonly in recent decades, as part of fixed-dose artemisinin-based combinations. In tablet form, each pill carries a defined dose of the bright yellow compound, available typically in 153 mg and 200 mg strengths. For pediatric use, dispersible formulations make dosing easier for parents and caregivers. The World Health Organization includes amodiaquine on its List of Essential Medicines, cementing its importance. Today, health agencies stockpile it for use during malaria outbreaks, and pilot programs distribute it widely for seasonal malaria chemoprevention across the Sahel region.
Amodiaquine Hydrochloride presents as a yellow to orange crystalline powder, relatively stable when protected from light and heat. In the laboratory, its melting point rests between 160-168°C, and it dissolves readily in water, sparking a faint bitter taste. The molecule's chemical formula, C20H22ClN3O·2HCl·2H2O, reflects its underlying structure: a 4-aminoquinoline core bearing a mannich base with a diethylaminomethyl substituent. Its molecular weight clocks in near 465.8 g/mol including the dihydrochloride dihydrate salts, crucial for proper dissolution and bioavailability in the digestive tract. Odd odors or color shifts signal degradation and hint at storage or packaging issues.
Pharmacopeial standards demand precise content uniformity and stringent purity; each batch must meet established limits for impurities, moisture, and assay values. Packaging materials shield the compound from humidity and sunlight, with tamper-resistant seals deterring contamination. Large-scale producers follow labeling requirements set by agencies such as the US Food and Drug Administration, the European Medicines Agency, and the World Health Organization’s Prequalification Programme. Boxed labels set forth the drug’s strength, manufacturing date, batch number, expiration, country of origin, storage recommendations, and a rundown of potential side effects. Health workers in remote areas often rely on these details, trusting the chain of documentation to guarantee safe administration.
The manufacturing process for amodiaquine hydrochloride draws on well-established organic synthesis routes. Starting from 4-chloroquinoline derivatives, chemists introduce the appropriate alkyl substitutions under controlled reaction conditions. Nucleophilic substitution with a p-aminobenzyl alcohol, followed by acidification with hydrochloric acid, yields the desired dihydrochloride salt. Operators monitor temperature, pH, and reaction time to suppress formation of crystalline byproducts that complicate purification. Filtration and recrystallization ensure that the final product meets purity specifications, while analytical chemists use thin-layer chromatography, HPLC, and spectroscopy to check each lot.
In chemical terms, amodiaquine's structure lends itself to further modification. By tweaking the alkyl groups or aromatic substitutions, medicinal chemists have generated a suite of analogs aimed at sidestepping drug resistance. Oxidative transformation in the body forms a carboxylic acid metabolite, which retains some antimalarial potential but changes the side effect profile. Efforts to attach fluorinated chains or to cyclize the terminal amine have yielded promising candidates during lead optimization. Each alteration brings a new set of pharmacokinetic and toxicity questions, and not all reach the level of clinical development.
In the world marketplace, amodiaquine hydrochloride goes by several names, such as Camoquin, Flavoquine, and Resochin-AQ. Regulators and researchers sometimes refer to it by CAS number 6398-98-7 or its IUPAC name, 4-[(7-Chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol dihydrochloride dihydrate. Documentation and procurement forms sometimes use only the acronym AQH or simply AQ, a shorthand preferred for ease in crowded field kits and rapid reporting systems.
Organizations such as the World Health Organization and the International Conference on Harmonisation lay out process controls across the pharmaceutical chain, from raw ingredient sourcing to final tableting. Factory workers wear gloves and eye protection to avoid skin and inhalation exposure, and ventilation systems curtail airborne dust. The hazards extend beyond the workplace, as improper use or overdosage can trigger hepatic or hematological complications. Training modules educate dispensers to watch for jaundice, easy bruising, or telltale patterns of infection. Regulatory authorities inspect flood-prone warehouses and clinics for expired stocks, supporting stewardship and prompt disposal protocols.
Most of the world's amodiaquine flows into malaria-endemic regions, especially sub-Saharan Africa, where seasonal spikes in disease coincide with the rainy season. During mass drug administration campaigns, health officials often combine amodiaquine with artesunate or sulfadoxine-pyrimethamine, building layered protection in vulnerable populations. In recent years, research studies have explored its role as a possible therapy in autoimmune and inflammatory disorders, drawing on structural similarities with hydroxychloroquine. Although not part of standard guidelines in these cases, clinicians in low-resource settings sometimes use it as a fallback when other options run thin.
Medical journals still devote frequent coverage to amodiaquine, evaluating its role in resistance management, new combination therapies, and safety in pregnancy or young children. Conducting pharmacogenomic surveys, scientists map population-level differences in metabolism and immune response, seeking ways to tailor dosing and reduce severe outcomes. Global partnerships run surveillance projects on the durability of artemisinin-amodiaquine therapy, publishing regular updates on efficacy in the face of evolving pathogens. Bench researchers continue to test derivative compounds against a range of parasites, including non-malarial species like leishmania or babesia, chasing broader-spectrum impact. Funding remains a challenge, with attention shifting each time a new infectious disease grabs headlines, but core research teams persist.
Studies on amodiaquine’s toxicity stretch back decades, painting a nuanced picture of benefit and risk. In therapeutic doses, the compound’s main problems include transient nausea and pruritus, but rare users experience hepatitis, neutropenia, and lethal agranulocytosis. Case series led to restrictions in use as monotherapy, pushing combination protocols to dilute peak exposures and extend clinical benefit. Laboratory scientists have mapped the molecular underpinnings: certain metabolites bind liver proteins, triggering immune-mediated cell death in susceptible individuals. The search for predictive genetics or early biomarkers now drives much of the toxicology discussion, as everyone agrees that survival from malaria should not cost a patient their future health.
Looking ahead, amodiaquine continues to shape the fight against infectious disease. Its place in seasonal chemoprevention draws praise for slashing pediatric hospital admissions, and global supply chains have grown more robust over the past ten years. Drug designers see its backbone as fertile ground for tweaking, prioritizing prototypes with improved resistance profiles or reduced toxicity. Nations in the tropics call for cost reductions, simplified dosing, and expanded patient education. Environmentalists debate the impact of pharmaceutical residues on local waterways, urging careful stewardship all the way from the factory gate to the sick child in a rural village. The challenge lies in balancing pragmatism with innovation—keeping reliable treatments on hand for those who need them now, while nurturing research for a future where the threat of malaria fades into memory.
Many people face health risks from malaria every year, especially in parts of Africa, South America, and Asia. Amodiaquine hydrochloride has been a cornerstone in the fight against malaria. My interest in this medicine goes back to spending time with public health teams during a trip to rural Nigeria, where stories about cholera and malaria were part of daily life. These communities see Amodiaquine not as a laboratory marvel, but a possible lifeline.
Amodiaquine belongs to a group of drugs called antimalarials. It gets prescribed most often for the treatment and prevention of malaria, particularly strains caused by Plasmodium falciparum and Plasmodium vivax. On my visit, community health workers detailed how basic access to this drug, usually combined with artesunate in what’s known as artesunate-amodiaquine therapy, can drop the death rates, especially in children under five. It matters hugely in areas where mosquitoes carrying drug-resistant parasites have made older medicines less useful.
Doctors trust amodiaquine because of its proven track record, and for many it’s one of a handful of treatments that work where chloroquine no longer helps. The World Health Organization (WHO) supports its use in combination with other medicines as part of artemisinin-based combination therapies.
For a lot of families, the experience of malaria isn’t just academic. High fever, chills, exhaustion, and the risk of deadlier complications isn’t something forgotten easily. In districts where amodiaquine has wide use, hospital stays often shorten, and fewer people suffer relapses. A report published by the WHO in 2022 counted millions of children given the seasonal malaria chemoprevention regimen—a short course repeated monthly during the rainy season—relying on amodiaquine along with sulfadoxine-pyrimethamine. This approach saves lives.
It isn’t perfect. Every medicine can have side effects; for amodiaquine, those include nausea, dizziness, or a risk of rare but serious blood disorders. Health workers take care to screen for possible reactions. Access also isn’t equal. In some villages farther from distribution centers, supplies mostly arrive after cases start rising, never before. This time lag weakens the benefits of preventive regimens. I’ve seen health posts run out of amodiaquine during heavy rains, with families forced to travel long distances—an experience shared from Ghana to Cameroon.
Fixing bottlenecks in distribution channels can make a huge difference. Increasing production or regional storage centers reduces shortages. Bringing in more local health workers, trained to identify people most at risk, would help reach vulnerable groups quickly, particularly young children and pregnant women. Digital tracking, even simple SMS reporting in areas with spotty internet, keeps tabs on medicine stocks better than manual logs. More needs to be invested in education so families trust and finish the full course, preventing partial treatment that encourages resistance. Long-term, research into vaccine programs might ease the pressure on medicines, but for now, amodiaquine remains a critical tool in the malaria fight. For those at risk, reliable access to this drug still means the difference between life and death.
Amodiaquine Hydrochloride stands as one of those malaria medicines that people count on, especially in places where the disease hits the hardest. Many community members, friends, and even relatives in malaria-prone regions rely on it. Every medicine brings its own list of possible side effects, and Amodiaquine definitely has a few that anyone using it should know. Drawing on years of talking to pharmacists and doctors—and after seeing how medicines play out in the real world—one lesson sticks: knowing what to expect can help keep people safer.
Everyday complaints come up most often with this medicine. Upset stomach, queasiness, and vomiting have shown up in more than a handful of cases. Feeling tired or dizzy makes it tough to handle daily chores, and sometimes headaches or joint pain join the party. Even kids have mentioned trouble finishing meals because of persistent nausea. Though these side effects usually fade after a day or two, the people I’ve spoken with often mention confusion—should they push through or call the clinic? Studies published in medical journals, like the British Journal of Clinical Pharmacology, repeatedly confirm these symptoms, so keeping an eye out helps avoid bigger trouble.
Some problems show up much less often, but when they do, they need action. Amodiaquine Hydrochloride links to liver trouble in certain cases. Signs like yellowing skin or eyes (doctors call it jaundice), dark pee, or aching under the ribs are all red flags. Once, in a rural clinic, a nurse shared a story about a patient who mistook early symptoms of liver damage for a stomach bug and delayed getting checked out—just a simple checkup could have stopped serious harm.On top of that, the medicine can drop a person’s white blood cell count, making infections more likely. High fevers, sore throats, and mouth ulcers sometimes point to this problem. Health journals, as well as official statements from the World Health Organization, stress that anyone facing these symptoms while taking amodiaquine should reach out quickly for blood tests.
People with liver disease, or those who’ve had trouble with medicines like this one before, should be extra cautious. I’ve met parents who mention their child’s long allergy history, or older adults worried about interactions with other medications. People living with HIV, using antiretroviral treatments, sit at higher risk for side effects—published research notes more frequent cases of bone marrow problems in these patients. If you’ve seen anyone in this position, you know how tricky dosing and timing can get. Having pharmacists nearby who know the medicine well helps families dodge bigger risks.
Open talk with healthcare workers matters most. Before starting any course of Amodiaquine Hydrochloride, make sure health backgrounds get shared honestly—other drugs, past liver issues, or allergies matter. Follow-up visits save lives, especially when lab testing can catch problems before symptoms even show. Keeping community education strong goes a long way: when neighbors remind each other about warning signs like fever or yellowing skin, people seek help faster.Some clinics in malaria hotspots have adopted training programs for health volunteers—teaching them to spot warning signs and push for early doctor visits. These measures, proven in fieldwork from both West and East Africa, offer real hope in catching life-threatening side effects quickly.
Medicines like Amodiaquine Hydrochloride do a lot of good, but side effects remain a reality people can’t ignore. Families, community leaders, and healthcare providers all play a part in turning information into action. Honest discussion, regular check-ins, and strong local education can help everyone get the real benefits of malaria treatment while steering clear of bigger risks.
Amodiaquine hydrochloride tackles malaria head-on, but this medicine carries its own set of rules. Your doctor gives you a dosing schedule, and following that schedule keeps you safest. I’ve seen more than one family member end up with bigger problems from malaria drugs being rushed or skipped. It’s important to take each dose at the time set by your healthcare provider—usually once daily with water, and often after a meal to help with stomach upset. Swallow the tablets whole; crushing them may seem easy, especially for kids, but it can change how the drug works or hurts your stomach lining.
Small bodies react differently to strong medicine. For children, calculation of the dose depends on weight. Under-dosing lets the malaria thrive, overdosing brings serious side effects. Pediatric liquid solutions exist, but the correct measurement matters. Families sometimes share medicines among siblings because “it worked for the older one”—that’s a dangerous myth. If the clinics are understaffed, push for the right dosing advice before giving the first spoonful to your child. Elderly people and those with weak livers need regular checkups, as amodiaquine can put extra stress on the liver. Don’t ignore signs like yellow skin or dark urine—let a professional know straight away.
The malaria parasite adapts fast. Stopping amodiaquine early fuels resistance and brings the disease back with a punch. I’ve read too many stories from health campaigns where families kept leftover pills “for next time.” That shortcut rarely works and weakens community efforts to beat malaria. Always take every pill. Even when you start to feel well, malaria lingers in the blood for a while. Most regimens last three days, but the instructions from your health provider are the ones to trust—each case differs.
Common side effects include nausea, headache, or tiredness. If vomiting happens within 30 minutes of swallowing the pill, another dose may be needed. Some people notice strange symptoms—itchy skin, dizziness, even low blood counts if taken for too long. Amodiaquine hydrochloride isn’t a casual remedy; always report anything unusual. Drug allergies aren’t rare in malaria highlands, so if a rash or swelling pops up, don’t try to manage it at home. Emergency service is your best bet.
Doctors often recommend using amodiaquine in combination with artemisinin-based therapy for better results. Self-mixing with painkillers or other unknown pills isn’t smart—interactions can ramp up toxicity. Pharmacy staff sometimes sell “combo packs,” but these aren’t substitutes for a licensed doctor’s guidance. Ask questions if anything looks strange on the label. Always disclose what medicines you’re taking, especially if someone else is writing the prescription, as this helps prevent risky overlaps.
Rural clinics often face hurdles—medicine shortages or a lack of dosing information in local languages. Health workers could improve outcomes with illustrated guides or dosing charts. Families gain more confidence, and patients understand treatments better with clear communication. Over-the-counter purchases without professional input often lead to confusion or improper dosing. Trusted, accessible education is as powerful as the medication itself.
Taking amodiaquine hydrochloride right is not just about fighting your own infection; it’s about protecting the whole community. Responsible use slows down resistance and keeps the drug effective for years to come. Malaria takes enough from us already—sticking to guidance helps tip the scales back in our favor.
Malaria hits hardest where it hurts most — kids and women expecting a child face the highest risks. In the last decade, parents in many African countries have relied on amodiaquine hydrochloride, either alone or with other medicines. My own encounters with malaria in rural clinics led to a tough question: What about the youngest patients, and mothers anticipating a new life?
The World Health Organization has vouched for amodiaquine as a partner drug in combination therapies when fighting malaria in areas plagued by resistance to older medicines. This strategy — giving two drugs, such as artesunate with amodiaquine — has kept malaria deaths in check for millions. Studies stretching across West and Central Africa show that children recover well, even the very young, with these combinations.
But lifesaving treatment sometimes demands a steep price. Side effects like vomiting, nausea, or rashes show up in clinics from Ghana to Nigeria. The concern rises when children suffer from repeated treatments, since amodiaquine can stress the liver or lower white blood cells. These risks follow unusually high or repeated doses, which means doctors must keep a close watch and make sure families receive accurate instructions. Families with a child suffering from malnutrition or with HIV face even more trouble, as weakened bodies break down medicine differently.
Pregnancy already pushes a woman’s body to the edge, and malaria does not hold back. Severe infections threaten both mother and unborn baby. In some areas, local clinics give pregnant women sulfadoxine-pyrimethamine to prevent malaria. Where drug resistance rises, health workers need substitutes. Amodiaquine has been used as one possible answer. Research over the last twenty years suggests that amodiaquine, given in short three-day courses, does not increase the danger of birth defects. Mothers experience roughly the same side effect risks as non-pregnant adults — mostly nausea and mild liver changes.
A louder alarm goes off with misuse or repeated doses. Longer use across pregnancy puts extra strain on the liver. Stories in community health centers confirm that overuse sometimes brings on more problems than it solves. Medical experts remind everyone: if a safer option is available, use it. Amodiaquine acts best as a backup or part of a combination, not as a first answer for every situation.
Sticking to proven guidelines protects those at greatest risk. Children under five and pregnant women deserve nothing less than precision in treatment. This means more training for village health workers, accessible leaflets in local languages, and continuous supplies of reliable combination therapies. Local pharmacies should avoid handing out amodiaquine for any fever, and doctors must screen for other health conditions before writing a prescription.
Researchers should keep punching holes in uncertainty around amodiaquine's safety in all trimesters and for kids with health complications. Health ministries owe it to their people to keep updating their advice every year, using fresh evidence.
No pill fixes all trouble. Smart, careful use of the medicines we have, plus real investment in frontline workers and families, keeps hope alive in communities where malaria no longer writes the ending for the most vulnerable.
I remember growing up watching family members pull out an entire handful of pills in the morning—blood pressure here, diabetes there, with a few vitamins mixed in. Both in person and through stories from people I trust, I’ve seen that combining medicines isn’t rare. For folks living in places where malaria hits hardest, amodiaquine hydrochloride often joins that lineup. The question sneaks up in almost every clinic line: Will this pill play nicely with any others?
Amodiaquine treats and helps prevent malaria. Sometimes, it’s paired with another drug—called artesunate—because together they kick malaria harder than either can alone. Yet, this doesn’t mean amodiaquine makes friends with every other prescription. Its chemistry can cross wires with some medicines, sometimes leading to side effects nobody wants.
For example, mixing amodiaquine with medicine like zidovudine, which treats HIV, can strain the liver far more. Anyone living with both malaria risk and HIV has to watch this, especially in West Africa where both threats loom over families every year. Research from the World Health Organization shows this concern isn’t just rare bad luck—it's a real risk that trips up more than a few households.
One big worry comes from painkillers and some heart pills, like those used to handle irregular heartbeats. Combining these with amodiaquine may stir up rhythm problems in the heart. Some antibiotics can cause issues, too—and certain medicines used for mental health treatment may not mix well either. I’ve even seen elderly patients, already tired from fever, get confused because the drugs triggered interactions doctors had to untangle fast. No one wants to play guessing games with their health.
Medicine cabinets don’t always come with detailed lists in every home. Too many times, I’ve seen someone stumble into trouble because those lists weren’t shared between doctors or clinics. The Centers for Disease Control keeps reminding folks that honest, up-to-date medicine records save lives—not just comfort. Knowing exactly what’s going into the body at any moment, including traditional or herbal remedies, gives health professionals their best shot at keeping things safe.
Doctors need the full story from patients, plain and simple. Rushed visits and incomplete information set up problems. Solutions can start simple, too: pocket notebooks listing every prescription, or just texting a family member with updates. Those tiny steps mean less risk if things go sideways.
Manufacturers and governments also carry weight here. Labeling that’s easy to understand helps. Public health campaigns explaining the risks of drug mixing—especially in communities hammered by both malaria and chronic illnesses—go a long way. Clear communication, from pharmacy to patient, can stop avoidable emergencies.
Taking amodiaquine hydrochloride with other medications isn’t just a technical problem for experts. It makes a difference in the lives of regular folks who just want to beat malaria and stay in good health. Speaking as someone who has watched how health choices ripple through families and neighborhoods, paying attention to these interactions matters every day.
| Names | |
| Preferred IUPAC name | 4-[(7-Chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol hydrochloride |
| Other names |
Camoquin Flavoquine Amodiaquinum Malarivon Malarquine |
| Pronunciation | /əˌmoʊdiəˈkwaɪn haɪˌdrɒkləˈraɪd/ |
| Identifiers | |
| CAS Number | 6398-98-7 |
| Beilstein Reference | 3582673 |
| ChEBI | CHEBI:3130 |
| ChEMBL | CHEMBLID: CHEMBL1567 |
| ChemSpider | 13472 |
| DrugBank | DB00613 |
| ECHA InfoCard | 100.018.223 |
| EC Number | 602-870-3 |
| Gmelin Reference | 53506 |
| KEGG | D07451 |
| MeSH | D004660 |
| PubChem CID | 21624176 |
| RTECS number | BQ5075000 |
| UNII | 508BT2GI2Y |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C20H23ClN4O·2HCl |
| Molar mass | 464.86 g/mol |
| Appearance | white or almost white crystalline powder |
| Odor | Odorless |
| Density | 0.98 g/cm³ |
| Solubility in water | Very soluble in water |
| log P | 3.7 |
| Acidity (pKa) | 10.3 |
| Basicity (pKb) | 6.7 |
| Magnetic susceptibility (χ) | -75.0e-6 cm³/mol |
| Refractive index (nD) | 1.656 |
| Dipole moment | 1.52 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 300.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -281.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | Std enthalpy of combustion (ΔcH⦵298) of Amodiaquine Hydrochloride: **-6694 kJ/mol** |
| Pharmacology | |
| ATC code | P01BA06 |
| Hazards | |
| Main hazards | Toxic if swallowed, causes eye and skin irritation, may cause allergic skin reaction, may cause respiratory irritation. |
| GHS labelling | GHS02, GHS07, GHS08 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Do not breathe dust or mist. Avoid contact with eyes, skin, and clothing. Wear protective gloves, protective clothing, eye protection, and face protection. Wash hands thoroughly after handling. Use only outdoors or in a well-ventilated area. |
| Lethal dose or concentration | LD50 (mouse, oral): 550 mg/kg |
| LD50 (median dose) | LD50 (median dose): 550 mg/kg (oral, mouse) |
| NIOSH | XP2718C980 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 17.86 |
| Related compounds | |
| Related compounds |
Amodiaquine Chloroquine Quinine Mefloquine Primaquine Pyrimethamine Sulfadoxine |
